Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study
Clinical medicine. Oncology · 2008
DOI: 10.4137/cmo.s1027 ↗At a glance
Journal article in Clinical medicine. Oncology, 2008. Written by Z Einbeigi and 3 co-authors. Institution: Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. 24 references. The full text is freely available in PubMed Central.
Abstract (original language)
Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m 2 , paclitaxel 155 mg/m 2 (both day 1) and capecitabine 665 mg/m 2 twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
Subjects
Author keywords
Authors and institutions
- Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden.
Cite
APA
Einbeigi, Z., Bergström, D., Hatschek, T., & Malmberg, M. (2008). Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s1027
Vancouver
Einbeigi Z, Bergström D, Hatschek T, Malmberg M. Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study. Clinical medicine. Oncology. 2008. doi:10.4137/cmo.s1027
BibTeX
@article{Einbeigi2008,
author = {Einbeigi, Z and Bergström, D and Hatschek, T and Malmberg, M},
title = {Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study},
journal = {Clinical medicine. Oncology},
year = {2008},
doi = {10.4137/cmo.s1027}
}
EUVIMED